Enrolling 47% of Total U.S. Participants for a Phase 3 Hepatology Trial

Science 37 was the top enrolling site, contributing 47% of total U.S. study participants. Despite joining the trial 6 months later, enrollment was 11x faster compared to the other 141 participating traditional brick-and-mortar sites. Science 37 also achieved an 82% retention rate in patients transferred from traditional sites who were at risk of dropping out.